Aligos Therapeutics focuses on ALG-000184 for CHB and ALG-055009 for MASH, targeting large, underserved markets with growing ...

Drug combination reaches key threshold for ‘functional cure’ of chronic liver infection that affects more than 250 million ...

Hepatitis B virus (HBV) infection contributes to hepatocellular carcinoma (HCC) tumorigenesis, drug resistance, and recurrence, although the ...

Researchers have uncovered a significant mechanism involved in liver fibrosis. Their findings have been published in the ...

Cryo-electron microscopy reveals the structural basis for the restriction of hepatitis B virus (HBV) entry in macaques, ...

Since liver disease has no noticeable symptoms in the early stages, the best thing you can do is proactively get tested. “It ...

Hepatitis B virus is a viral infection which affects the liver and can result in permanent liver damage. It is currently the leading cause of chronic liver | Immunology ...

AstraZeneca's IMFINZI® (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following ...

Liver cancer is one of the deadliest cancers worldwide, often developing silently in an organ crucial for metabolism, energy ...

Hepatitis B virus (HBV) infection is a leading cause of chronic liver diseases, that spreads among individuals through blood ...

Tune Therapeutics, an epigenome-editing company based in Durham and Seattle, will be the first to initiate a human clinical trial for an epigenetic therapy for a common infectious disease.

Primary Endpoint Achieved with 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) after Short Eight Week Treatment Duration ...